Dyadic International (DYAI) Expected to Announce Quarterly Earnings on Wednesday

Dyadic International (NASDAQ:DYAI) is anticipated to post its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $1.0250 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 5:00 PM ET.

Dyadic International (NASDAQ:DYAI) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The firm had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. On average, analysts expect Dyadic International to post $0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Dyadic International Trading Up 3.2%

Shares of DYAI opened at $1.11 on Wednesday. Dyadic International has a 12-month low of $0.65 and a 12-month high of $1.60. The stock’s fifty day simple moving average is $0.94 and its 200-day simple moving average is $0.86. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The firm has a market capitalization of $40.63 million, a PE ratio of -4.85 and a beta of 1.12.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DYAI. Geode Capital Management LLC increased its stake in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in Dyadic International in the 3rd quarter valued at approximately $190,000. Finally, Bank of America Corp DE boosted its position in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Dyadic International currently has an average rating of “Hold” and a consensus target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.